cor2ed
engage checkpoint medical linkedin twitter
bg

PARP inhibitors in prostate cancer and the rationale behind combination treatment

PARP inhibitors in prostate cancer and the rationale behind combination treatment

A 2-part micro e-learning programme with videos and downloadable resources

A 2-part micro e-learning programme with videos and downloadable resources

Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno

In this micro e-learning programme, you'll learn about PARP inhibitors in prostate cancer from independent experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno. 

Module 1 covers the use of PARP inhibitors as monotherapy in advanced prostate cancer, and in module 2, the experts will explore the rationale behind combination treatment with anti-androgens. After watching the videos, take the assessments to earn your CME credit.

 

Clinical takeaways:

  • PARP inhibitors are effective drugs as monotherapy in mCRPC patients with HRR alterations
  • Genetic testing is important to help with treatment decision-making and for understanding inherited risk
  • BRCA mutations are associated with poor outcomes in mCRPC patients
  • Patients with tumours harbouring BRCA1/BRCA2 alterations appear to derive the greatest clinical benefit from PARPi, but patients with other HRR alterations also derive benefit
  • PARP inhibitors combined with novel hormonal agents are effective as a first-line treatment option for mCRPC patients with an HRR mutation. Certain combinations, such as olaparib plus abiraterone, have also shown benefits in patients regardless of their HRR status

 

This PARP Inhibitors in Prostate Cancer micro e-learning programme is endorsed by 

Portrait of Dr. Alicia Morgans
Assoc. Prof. Alicia Morgans

Medical Oncologist

Dana-Farber Cancer Institute

United States (US)

Dr Pasquale Rescigno

Clinical Senior Lecturer

Newcastle University

United Kingdom (UK)

preview next

Module 1 - PARP inhibitors in advanced prostate cancer

time Micro E-learning | open 4 min |accreditation: EACCME | Jan 2023

I agree that this educational programme:

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

time Micro E-learning | open 4 min |accreditation: EACCME | Jan 2023

I agree that this educational programme:

 

 

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) and ECMEC® is available. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

This educational programme is supported by an Independent Medical Education Grant from AstraZeneca

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Other programmes of interest

Other programmes developed by Assoc. Prof. Alicia Morgans

Portrait of Dr. Alicia Morgans
Assoc. Prof. Alicia Morgans

Medical Oncologist

Dana-Farber Cancer Institute

United States (US)

preview next